Lübeck-based Perfood has closed a €5 million Series A financing round led by German Boehringer Ingelheim Venture Fund. German family office UV-Cap and Swiss investment platform investiere joined the round as co-investors.
Founded in 2017 by CEO Dominik Burziwoda, Chief Medical Officer Dr Torsten Schröder, CTO Dr Christoph Twesten, and Prof. Dr Christian Sina at the University of Lübeck, Perfood develops a pipeline of digital therapeutics powered by personalized, blood sugar-stabilizing nutrition. The company is now working on its first prescription therapeutic product sinCephalea for the treatment of migraine.
sinCephalea is a three months lasting digital therapy program that consists of a personalized stable-glycemic diet based on Perfood Nutrilytics™ technology and experts supports. It is aimed to prevent migraines before they happen.
Perfood is planning to use the raised funds for launching its sinCephalea therapy and to prepare the expansion of the technology into other indications. This includes the conductions of clinical studies to advance its pipeline of digital therapeutics products, the company notes.
Leading investor Boehringer Ingelheim Venture Fund specialises on strategic investments in early-stage biotech and startups with innovative concepts and technologies that have the potential to provide ground-breaking therapeutic platforms.
